Related Experiment Videos
Atorvastatin affects C-reactive protein levels in patients with coronary artery disease
Ilgin Karaca1, Erdoğan Ilkay, Mehmet Akbulut
1Firat University Medical School, Elaziğ, Turkey. ilgink@yahoo.com
Insights
Atorvastatin significantly reduced C-reactive protein (CRP) levels in coronary artery disease (CAD) patients, indicating an anti-inflammatory effect. This reduction was observed independently of changes in cholesterol levels.
Area of Science:
- Cardiology
- Pharmacology
- Inflammation Research
Background:
- Elevated C-reactive protein (CRP) is a marker of poor prognosis in coronary artery disease (CAD).
- Understanding the anti-inflammatory properties of statins is crucial for managing CAD.
- Atorvastatin is a commonly prescribed statin for cardiovascular risk reduction.
Purpose of the Study:
- To evaluate the anti-inflammatory effects of atorvastatin in patients with CAD.
- To measure changes in serum CRP levels as an indicator of inflammation.
- To assess if the anti-inflammatory effect is linked to lipid-lowering properties.
Main Methods:
- A study involving 78 patients with CAD.
- Patients were divided into two groups: one receiving atorvastatin (20 mg/day) plus standard treatment, and a control group receiving only standard treatment.
- Serum CRP levels and lipid profiles were measured at baseline and after 4 weeks of treatment.
Main Results:
- In the atorvastatin group, CRP levels decreased significantly from 20.3 mg/dl to 10.8 mg/dl (p < 0.001).
- In the control group, CRP levels also decreased from 17 mg/dl to 12.8 mg/dl (p < 0.01).
- The reduction in CRP was significantly greater in the atorvastatin group compared to the control group (p = 0.003).
Conclusions:
- Atorvastatin demonstrates a significant anti-inflammatory effect in patients with CAD by reducing CRP levels.
- This anti-inflammatory action of atorvastatin is independent of its effects on low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C).
- These findings highlight a potential direct anti-inflammatory benefit of atorvastatin in cardiovascular disease management.
Background:
Elevated levels of C-reactive protein (CRP) are considered to be one of the indicators of poor prognosis in coronary artery disease (CAD). The aim of this study was to evaluate anti-inflammatory effects of atorvastatin in patients with CAD by measuring serum CRP levels.
Methods:
After measuring the baseline levels of CRP and lipid fractions, the patients were divided into two groups. In Group A (n = 46), atorvastatin (20 mg/day) was administered in addition to classic antianginal treatment (beta-blocker, nitrate and aspirin). In Group B (n = 32), the usual antianginal treatment was continued. Following 4 weeks of treatment the same measurements were repeated.
Results:
In Group A, CRP decreased from 20.3 mg/dl (95% CI, 9-31.8) to 10.8 mg/dl (95% CI, 2.7-18.9) (p < 0.001). In Group B, CRP decreased from 17 mg/dl (95% CI, 13.1-21) to 12.8 mg/dl (95% CI, 9.7-15.9) (p < 0.01). The decrease in group A was more than in group B (p = 0.003).
Conclusions:
In patients with CAD, atorvastatin exerted an anti-inflammatory effect represented by decreasing CRP levels. This effect was independent of the change in low density lipoprotein cholesterol (LDL-C) or high density lipoprotein cholesterol (HDL-C) levels.